Decoding the WHO Global Tuberculosis Report 2024: A Critical Analysis of Global and Chinese Key DataZhi Chen, Wenping Gong, Lirong Mao et al.|Zoonoses|2025Cited by 61
Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2Shengshan Xu, Yuchen Liu, Xiguang Chen et al.|Frontiers in Immunology|2023Cited by 26
Reduced VMAT2 expression exacerbates the hyposmia in the MPTP model of Parkinson's diseaseKai Ma, Tao Wang, Chao Han et al.|Biochemical and Biophysical Research Communications|2019Cited by 11
Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.Elias Jabbour, Hagop M. Kantarjian, Nicola Gökbuget et al.|Journal of Clinical Oncology|2018Cited by 6